Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Altimmune, Inc. (NASDAQ:ALT) have earned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $16.6667.

ALT has been the topic of several research reports. William Blair reaffirmed a “market perform” rating on shares of Altimmune in a research report on Thursday, March 5th. Wall Street Zen downgraded Altimmune from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. B. Riley Financial reduced their price target on Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Truist Financial started coverage on Altimmune in a research report on Wednesday, March 18th. They set a “buy” rating and a $12.00 price target on the stock. Finally, Citigroup reissued a “market outperform” rating on shares of Altimmune in a research report on Tuesday, June 2nd.

Altimmune Price Performance

Altimmune stock opened at $2.70 on Tuesday. Altimmune has a 12 month low of $2.56 and a 12 month high of $7.73. The stock’s 50 day moving average is $2.96 and its 200-day moving average is $3.82. The company has a current ratio of 29.56, a quick ratio of 29.56 and a debt-to-equity ratio of 0.12. The company has a market capitalization of $525.07 million, a price-to-earnings ratio of -2.90 and a beta of 0.21.

Altimmune (NASDAQ:ALT) last posted its earnings results on Wednesday, May 13th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.07. Altimmune had a negative return on equity of 42.57% and a negative net margin of 214,860.98%. Equities research analysts expect that Altimmune will post -0.69 EPS for the current year.

Institutional Investors Weigh In On Altimmune

A number of large investors have recently added to or reduced their stakes in ALT. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Altimmune by 4.8% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company’s stock worth $247,000 after buying an additional 2,241 shares in the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of Altimmune during the 1st quarter worth approximately $50,000. Envestnet Asset Management Inc. boosted its position in shares of Altimmune by 48.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 32,908 shares of the company’s stock worth $127,000 after acquiring an additional 10,671 shares in the last quarter. Creative Planning boosted its position in shares of Altimmune by 30.2% during the 2nd quarter. Creative Planning now owns 41,164 shares of the company’s stock worth $159,000 after acquiring an additional 9,558 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Altimmune by 7.0% in the second quarter. Rhumbline Advisers now owns 113,981 shares of the company’s stock valued at $441,000 after acquiring an additional 7,462 shares during the last quarter. Institutional investors and hedge funds own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.